19th March 2024 - 21 March, 2024
Hilton Boston Back Bay
Uniting KOLs, industry experts and regulators at the forefront of kidney disease research, the 6th CKD Drug Development Summit is biopharma’s must-attend forum for staying up to date with the latest breakthroughs in surrogate endpoint innovation, novel pathway and target exploration, the advancement of personalized therapies, and much more.
What’s new for 2024:
- 60+ Brand New Speakers: Broaden your network of industry peers working across diabetic, hypertensive and rare kidney disease with fresh faces brining novel insights from the likes of Regeneron, HI-Bio, GSK, Novo Nordisk, Eli Lilly and Vertex Pharmaceuticals
- The First IgA Nephropathy Seminar Day: Deepen understanding of pathophysiology and genetic architecture to explore new targets, discover the latest complement, APRIL and BlyS clinical data, and discuss the integration of emerging IgAN treatments into evolving care standards with Calliditas, Otsuka, Novartis, Genentech, Takeda, Vera Therapeutics, Alexion and more.
- Three Dedicated Tracks of Content: Bring your team for highly focused discussions on three distinct areas: target discovery and preclinical CKD models, exploratory biomarkers and early clinical innovation, and regulatory-accepted clinical endpoints and outcomes research.